AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04707313
Drug: Placebo (Cohorts 1 and 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 matching placebo tablets taken twice daily
Trial: NCT04707313
Drug: Placebo (Cohort 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 matching placebo tablets taken twice daily
Trial: NCT06538558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
Trial: NCT05943886
Drug: HEC88473 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Trial: NCT05943886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by subcutaneous injection in the abdomen.
Trial: NCT05120362
Drug: Cream containing JAK Inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug is a cream containing JAK Inhibitor.
Trial: NCT05894486
Drug: Lutetium[177Lu] Oxodotreotide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
Trial: NCT05975983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Trial: NCT04913779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
Trial: NCT05100199
Drug: OnabotulinumtoxinA X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT06164327
Drug: BEBT-908 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
Trial: NCT04970342
Drug: Placebo (Lactose) Capsule
RxNorm normalized name: lactose Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
Trial: NCT04996264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
Trial: NCT04996264
Drug: Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
Trial: NCT05977400
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Gentamicin
Trial: NCT05977400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Normal Saline
Trial: NCT05874284
Drug: Gelofusin
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
Trial: NCT05147376
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
Trial: NCT03656029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will smoke a placebo cigarette
Trial: NCT06518044
Drug: N Acetyl L Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
Trial: NCT05288348
Drug: Sufentanil 30 MCG Sublingual Tablet
RxNorm normalized name: SUFentanil 30 MCG Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microgram sublingual tablet administered using sublingual applicator
Trial: NCT05288348
Drug: standard care pain treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care pain treatment given in Emergency Department
Trial: NCT05951946
Drug: BR3006-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Trial: NCT05951946
Drug: BR3006-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Trial: NCT05951946
Drug: BR3006-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Trial: NCT05297448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Twice Daily
Trial: NCT05616468
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Trial: NCT05677438
Drug: CKD-498 dose#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT05677438
Drug: CKD-498 dose#2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT05677438
Drug: CKD-498 dose#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT05677438
Drug: Placebo of CKD-498 dose#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT05677438
Drug: Placebo of CKD-498 dose#2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT05677438
Drug: Placebo of CKD-498 dose#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily, 24 weeks
Trial: NCT04752163
Drug: DS-1594b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given DS-1594b PO
Trial: NCT04752163
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04752163
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT04752163
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT06079320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablets from Day 1 to Day 5
Trial: NCT05222828
Drug: Carbocaine Injectable Product
RxNorm normalized name: Carbocaine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection per patient
Trial: NCT05373446
Drug: SSD8432 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
Trial: NCT05373446
Drug: SSD8432 750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
Trial: NCT05373446
Drug: SSD8432Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
Trial: NCT04727424
Drug: Fluoxetine 20 MG
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.
Trial: NCT04727424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)
Trial: NCT05250141
Drug: Levodopa 250mg and Carbidopa 25mg Test Drug tablet
RxNorm normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT05250141
Drug: Levodopa 250mg and Carbidopa 25mg Referent Product tablet
RxNorm normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sinemet (Savio Industrial S.R.L, Brazil)
Trial: NCT05664100
Drug: FX-345
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of FX-345
Trial: NCT05664100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of placebo
Trial: NCT05401227
Drug: Ts-134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days of TS-134 20 mg
Trial: NCT05401227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days of placebo TS-134
Trial: NCT05286762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized at Visit 2 to Placebo
Trial: NCT01363700
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05153564
Drug: NNC0480-0389 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Trial: NCT05153564
Drug: NNC0480-0389 30 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Trial: NCT05153564
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Trial: NCT05862610
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
Trial: NCT05014672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05724472
Drug: rVSV∆G-SEBOV-GP Vaccine or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV∆G-SEBOV-GP Vaccine or Placebo
Trial: NCT04954196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks.
Trial: NCT05642585
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral
Trial: NCT05642585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral
Trial: NCT06675994
Drug: PCSK9 Antibody, PCSK9 Enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
Trial: NCT06676410
Drug: Dispensing Codivir®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the participant receives Codivir®
Trial: NCT06676410
Drug: Antiretrovirals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day
Trial: NCT05069051
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients obtain the standard of care: combination rituximab and venetoclax
Trial: NCT05557344
Drug: Acetaminophen IV
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
Trial: NCT05557344
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
Trial: NCT05173883
Drug: injection ，CU-20401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection，cohort A 6 sites
Trial: NCT05173883
Drug: injection ，placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection，just one site
Trial: NCT05076552
Drug: TACH101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally via capsules
Trial: NCT06139315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05011812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT05047341
Drug: SHR0302、[14C]SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
Trial: NCT04881318
Drug: Medications that modulate heart rate and blood pressure
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
Trial: NCT04802811
Drug: SHR2150；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose；SHR2150-dose 1 or Placebo-dose 1
Trial: NCT04802811
Drug: SHR2150；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose；SHR2150-dose 2 or Placebo-dose 2
Trial: NCT04802811
Drug: SHR2150；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose；SHR2150-dose 3 or Placebo-dose 3
Trial: NCT04802811
Drug: SHR2150；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose；SHR2150-dose 4 or Placebo-dose 4
Trial: NCT04802811
Drug: SHR2150；Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose；SHR2150-dose 5 or Placebo-dose 5
Trial: NCT06287931
Drug: Ursodoxycholic acid group
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodoxycholic acid, 250mg po tid x 6 months
Trial: NCT05579223
Drug: Intrathecal Placebo Mono Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
Trial: NCT05445895
Drug: Renexin CR 200/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renexin CR 200/160mg will be added to Aspirin 100mg
Trial: NCT05936671
Drug: Sevoflurane and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
Trial: NCT06172686
Drug: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
Trial: NCT06357910
Drug: HCP2303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet once per period
Trial: NCT06357910
Drug: RLD2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet once per period
Trial: NCT05481775
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
Trial: NCT05481775
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
Trial: NCT06422650
Drug: Nigella Sativa capsule 500mg
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella Sativa capsule 500mg twice daily for 8 weeks
Trial: NCT06422650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo identical to astaxanthin
Trial: NCT04573803
Drug: Phenytoin Sodium
RxNorm normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
Trial: NCT04645446
Drug: Pro-ocular gel
RxNorm normalized name: Denticare Pro Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Trial: NCT04645446
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Trial: NCT05528055
Drug: SCR-6920 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
Trial: NCT05528055
Drug: SCR-6920 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
Trial: NCT05383209
Drug: EYP-1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT06139341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04712669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 matching placebo tablets on top of standard of care